Jan Mattsson - 18 Jan 2022 Form 4 Insider Report for ALBIREO PHARMA, INC.

Role
Chief Scientific Officer
Signature
/s/ Jason Duncan, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 15:54:53 UTC
Next filing
25 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALBO Common Stock Award $0 +21,600 +57% $0.000000 59,174 18 Jan 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026.
F2 Represents 32,074 shares of common stock and 27,100 restricted stock units.